Verve Therapeutics reports Q4 EPS (58c), consensus (67c)

Reports Q4 revenue $13.08M, consensus $4.24M. Cash, cash equivalents, and marketable securities were $524.3M as of December 31, 2024, compared with $624.0M as of December 31, 2023. Verve expects its capital position, including the milestone payment received from Lilly in February 2025, to be sufficient to fund its operations into mid-2027. “2024 was a year of strong execution as we made crucial progress across our pipeline and laid the groundwork for 2025 to be a milestone-rich year for Verve,” said Sekar Kathiresan, CEO. “Enrollment for the Heart-2 Phase 1b clinical trial of VERVE-102 is progressing well, and dosing in the third cohort continues. As of February 13, 2025, VERVE-102 continues to be well-tolerated, and we are on track to report initial data from the Heart-2 trial in the second quarter of this year. We anticipate additional milestones in the second half of 2025, including final data from the dose escalation portion of the Heart-2 trial, delivery of the opt-in package and an opt-in decision from Lilly on the PCSK9 program, as well as a program update for VERVE-201, our program targeting ANGPTL3…Supported by a strong balance sheet, we are excited about the opportunities ahead as we advance our pipeline of one-time treatments that have the potential to offer a lifetime of benefit for cardiovascular disease patients.”